Table 1.
Celiac disease | Microscopic colitis | |||||
---|---|---|---|---|---|---|
Quiescent | Active | P | Collagenous | Lymphocytic | P | |
N | 51 | 9 | 34 | 32 | ||
Sex (M/F) | 10/41 | 3/6 | 0.4 | 7/27 | 3/29 | 0.2 |
Age (years) | 53 (37–64) | 36 (23–50) | 0.03 | 66 (54–72) | 58 (45–69) | 0.2 |
BMI (kg/m2) | 23 (21–29) | 22(19–32.8) | 0.8 | 25 (20–29) | 23.3 (20.5–30) | 0.8 |
Cholecystectomy | 24% (12/51) | 22% (2/9) | 0.9 | 18% (6/31) | 28% (9/32) | 0.3 |
Fecal fat (g) | 7 (3.5–13) | 9.5 (4.3–12.3) | 0.8 | 8 (5–10) | 7 (4–10) | 0.7 |
48 h fecal wt (g) | 421(267–748) | 577 (458–812) | 0.2 | 645 (409–941) | 546 (447–838) | 0.5 |
BM/day | 5 (3–6) | 5.8 (2.6–7.9) | 0.6 | 7 (4.5–10) | 6.5 (5–10) | 0.8 |
Stool BSFS (range 1–7-point scale) | 6(5.4–7) | 5.5 (5–6) | 0.1 | 6 (6–7) | 6.5 (6–7) | 0.3 |
% primary BA | 3.7 (1–25) | 14.5 (1.6–70) | 0.1 | 5.6 (1.1–21.7) | 4.9 (1.2–27) | 0.9 |
Total fecal BA μmol/48 h | 767 (288–1758) | 882 (355–2363) | 0.7 | 727 (450–1889) | 1131 (446–2091) | 0.5 |
Primary BA (μmol/mL) | 0.04 (0.02–0.8) | 0.06 (0.02–2.4) | 0.7 | 0.05 (0.02–0.3) | 0.07 (0.02–0.8) | 0.5 |
Primary BA ≥ 1.25 μmol/mL (%) | 20% (10/51) | 33% (3/9) | 0.3 | 9% (3/34) | 19% (6/32) | 0.24 |
↑ Primary IBAX | 25% (13/51) | 33% (3/9) | 0.9 | 35% (12/34) | 31% (10/32) | 0.9 |
↑ Total IBAX | 22% (11/51) | 22% (2/9) | 0.9 | 18% (6/34) | 19% (6/32) | 0.9 |
↑ BA (primary or total IBAX) | 47% (24/51) | 56% (5/9) | 0.9 | 53% (18/34) | 50% (16/32) | 0.9 |
M, male; F, female; Wt, weight; BM, bowel movement; BSFS, Bristol Stool Form Scale;BA, bile acid; IBAX, increased bile acid excretion
Celiac disease was subdivided into quiescent and active disease from serum and endoscopic evaluation. Microscopic colitis was subdivided into collagenous and lymphocytic colitis based on pathology specimens. Data show median (IQR); ↑ = increased; the row showing ↑ BA (primary or total IBAX) reflects data in the two preceding rows